Share this article
Share this article
SAN DIEGO, March 12, 2021 /PRNewswire/ Angiocrine Bioscience Inc., a clinical-stage biopharmaceutical company today announced that they have been selected by the European Society for Blood and Marrow Transplantation (EBMT) for an oral presentation of from AB-205-001, a Phase 1b/2 study to prevent progression to severe organ toxicities in lymphoma subjects undergoing curative high-dose consolidation therapy with autologous hematopoietic cell transplantation (HDT-AHCT). Our investigators and Angiocrine are honored to be selected by EBMT to present at its annual meeting this March, commented Paul Finnegan, MD, Angiocrine CEO. We look forward to Dr. Caroline Mulroney s presentation of AB-205 s efficacy and safety results from our Phase 1b/2 study as well as preparing for the upcoming Phase 3 registration study for this indication.
Angiocrine Bioscience Announces Oral Presentation of AB-205 Data during the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
MaaT Pharma to Provide Clinical Data for Lead Microbiome Ecosystem Therapeutic MaaT013 in Intestinal Acute GvHD at Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
Topline data from the Phase 2 HERACLES clinical trial with MaaT013 will be announced near-term MaaT Pharma announced today that data from its early access program for lead microbiome ecosystem therapeutic, MaaT013, will be reported in an oral presentation at the virtual 47
th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) taking place from March 14 March 17, 2021. The data was previously presented at the American Society of Hematology in December 2020. MaaT013 is an enema formulation of a full ecosystem microbiota biotherapeutic characterized by a consistent high diversity and richness of microbial species derived from pooled healthy donors The results include data from 29 patients with gastrointestinal, acute Graft-versus-Host-Disea